Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

PlexusDx vs TeleHealth Med

PlexusDx
Graded #162

Higher grade

vs+1.6000000000000085
TeleHealth Med
Graded #209

Lower grade

The verdict

PlexusDx takes it — 67.7/100 to 66.1/100, but only just.

PlexusDx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PlexusDx (plexusdx.com) is a US GLP-1 telehealth platform offering compounded weight-loss medications with licensed providers in all 50 states. TeleHealth Med is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
74
74
Dose & formulationPlexusDx +1
64
63
Clinical oversightTeleHealth Med +2
74
76
Labs & monitoringEven
52
52
FulfillmentPlexusDx +15
78
63
Contract termsEven
55
55
PlexusDx · left barTeleHealth Med · right bar

The numbers

MetricPlexusDxTeleHealth Med
WeighScore67.7/10066.1/100
GradeCC
Scorecard rank#162#209
Semaglutide$149/mo (starting dose, compounded)$147/mo (starting dose, compounded)
Tirzepatide$249/mo (starting dose, compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
PlexusDx

Graded #162 · C

Strengths

  • Licensed providers available in all 50 states
  • Range of options including low-cost microdose GLP-1 from $129/mo
  • Optional Precision Peptide genetic panel adds a personalization angle
  • Independent clinician review via state-licensed telehealth platform
  • Compounded medications from state-licensed pharmacies

Where it loses points

  • Compounded medications only; no FDA-approved brand options
  • Specific compounding pharmacies not named
  • Genetic-panel upsell may not add clinical value for everyone
  • Tirzepatide pricing from $249/mo is higher than budget rivals
  • No insurance accepted
TeleHealth Med

Graded #209 · C

Strengths

  • Corporate entity disclosed (TeleHealth Med, Inc.) — clearer accountability than undisclosed competitors
  • Publishes the FDA compounded-medication disclaimer
  • 503A pharmacy designation stated in the FAQ
  • Honest disclosure that testimonials are compensated and results aren't independently verified
  • Both injectable and sublingual forms offered

Where it loses points

  • Specific 503A pharmacy partner not named
  • LegitScript ID number not shown in text — only a verification link
  • Full states-served list not disclosed
  • Named medical director not disclosed
  • Dose tiers beyond the $147/mo starting price not published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard